Amanote Research
Register
Sign In
Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis
Neurology: Neuroimmunology and NeuroInflammation
- United States
doi 10.1212/nxi.0000000000000116
Full Text
Open PDF
Abstract
Available in
full text
Categories
Neurology
Date
May 14, 2015
Authors
Unknown
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related search
Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis
Neurology: Neuroimmunology and NeuroInflammation
Neurology
Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis
Prescriber
Pharmacology
Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment
Annals of Clinical and Translational Neurology
Neuroscience
Neurology
Dimethyl Fumarate Treatment Alters NK Cell Function in Multiple Sclerosis
European Journal of Immunology
Allergy
Immunology
Dimethyl Fumarate for the Treatment of Plaque Psoriasis
Prescriber
Pharmacology
Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases
Frontiers in Immunology
Allergy
Immunology
Immunofluorescent Staining of Rat Brain Glial Cells With Multiple Sclerosis Serum
Canadian Journal of Neurological Sciences
Medicine
Neurology
Glial Cells in Amyotrophic Lateral Sclerosis
Neurology Research International
Neurology
Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two-Year Experience
Multiple Sclerosis Journal – Experimental, Translational and Clinical
